• The antibody contract manufacturing market is projected to reach USD 17 billion by 2030

    With over 100 therapeutic monoclonal antibodies and antibody-based products in the market, the demand for developing and manufacturing of such products is anticipated to increase beyond the capabilities of innovator companies alone

    For additional details, please visit
    https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html
    The antibody contract manufacturing market is projected to reach USD 17 billion by 2030 With over 100 therapeutic monoclonal antibodies and antibody-based products in the market, the demand for developing and manufacturing of such products is anticipated to increase beyond the capabilities of innovator companies alone For additional details, please visit https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html
    Antibody Contract Manufacturing | Industry Analysis | Market Size | 2030
    Market research report on antibody contract manufacturing market, with a focus on current landscape and future growth opportunities
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The antibody contract manufacturing market is projected to reach USD 17 billion by 2030, growing at an annualized rate of 12%

    With over 100 therapeutic monoclonal antibodies and antibody-based products in the market, the demand for developing and manufacturing of such products is anticipated to increase beyond the capabilities of innovator companies alone

    For additional details, please visit
    https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html
    The antibody contract manufacturing market is projected to reach USD 17 billion by 2030, growing at an annualized rate of 12% With over 100 therapeutic monoclonal antibodies and antibody-based products in the market, the demand for developing and manufacturing of such products is anticipated to increase beyond the capabilities of innovator companies alone For additional details, please visit https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html
    Antibody Contract Manufacturing | Industry Analysis | Market Size | 2030
    Market research report on antibody contract manufacturing market, with a focus on current landscape and future growth opportunities
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The biopharmaceutical excipient manufacturing market is projected to grow at an annualized rate of 5.8%

    The demand for biopharmaceutical excipients has grown considerably in the past few years; they play a critical role in biologics development by enhancing the solubility and bioavailability, controlling pH and tonicity of the active pharmaceutical ingredients (APIs)

    Roots Analysis has announced the addition of “Biopharmaceutical Excipient Market” report to its list of offerings

    Owing to the highly complex and capital-intensive manufacturing processes of biopharmaceutical excipients, many contemporary biologic developers prefer to rely on CMOs for the supply of GMP grade excipients. In order to cater to the growing demand for biopharmaceutical excipients across both clinical and commercial scales, CMOs with expertise in this field are anticipated to expand their capabilities and existing capacities in the coming years.

    To order this 200+ page report, which features 75+ figures and 110+ tables, please visit
    https://www.rootsanalysis.com/reports/biopharmaceutical-excipient-manufacturing-market.html

    Key Market Insights

    Over 40 companies, across the world, claim to offer biopharmaceutical excipients
    Majority of the firms (34%) engaged in this domain are mid-sized players, followed by large firms (32%) and very large companies (19%). Close to 30% of the stakeholders were established post 2000. Further, 37% players are based in North America; within this region, the US emerged as a most prominent hub.

    Partnership activity within this domain has grown at a CAGR of 70%, between 2016 and 2021
    Over 40 agreements have been inked in the last 5 years in this domain; 32% of which were distribution agreements. Other popular types of partnership models adopted by players engaged in this domain include acquisitions (23%) and supply agreements (13%).

    ~ 40% rise in expansion initiatives in this field, during the period 2016-2021
    More than 45% of such initiatives were focused on capacity expansion of manufacturing facilities, followed by those undertaken for expanding existing facilities (43%). It is worth mentioning that most of expansion initiatives (78%) were carried out in Europe and North America.

    Approximately 95% of the total installed capacity is dedicated to commercial scale manufacturing
    The remaining 5% of the installed capacity is focused on preclinical / clinical scale manufacturing of biopharmaceutical excipients. In addition, over 50% of the total current global, installed biopharmaceutical excipient manufacturing capacity is installed in Europe.

    North America and Europe are anticipated to capture over 70% of the market share, by 2035
    In addition, the market in Asia Pacific is likely to grow at a relatively faster pace (6.4%) in the long term. Further, in 2035, biopharmaceutical excipient manufacturing market for antibodies is expected to capture the majority share (~52%) of the total market.

    To request a sample copy / brochure of this report, please visit
    https://www.rootsanalysis.com/reports/biopharmaceutical-excipient-manufacturing-market.html

    Key Questions Answered
     Who are the key players engaged in biopharmaceutical excipient manufacturing?
     Which global regions are considered as key hubs for biopharmaceutical excipient manufacturing?
     What type of partnership models are commonly adopted by stakeholders in this industry?
     What kind of expansion initiatives have been undertaken by biopharmaceutical excipient manufacturers?
     What is current, global biopharmaceutical excipient manufacturing capacity of contract manufacturers?
     How is the current and future market opportunity likely to be distributed across key market segments?

    The financial opportunity within the protein design and engineering services market has been analyzed across the following segments:

     Type of Biologic
     Antibodies
     Vaccines
     Cell and Gene Therapies
     Other Biologics

     Type of Excipient
     Carbohydrates
     Polymers
     Solubilizers / Surfactants
     Polyols
     Proteins / Amino Acids
     Others

     Company Size
     Small
     Mid-Sized
     Large / Very Large

     Scale of Operation
     Preclinical
     Clinical
     Commercial

     Key Geographical Regions
     North America
     Europe
     Asia-Pacific
     Latin America
     MENA
     Rest of the World

    The report also features inputs from eminent industry stakeholders, according to whom, growing demand for biopharmaceutical excipients will drive the growth of manufacturers engaged in the biopharmaceutical excipient manufacturing domain, in the coming future.

    The research includes profiles of key players (listed below); each profile features a brief overview of the company, financial information (if available), details related to its biopharmaceutical excipients portfolio, manufacturing facilities, recent developments, and an informed future outlook.
     ABITEC
     Avantor
     BASF
     Corden Pharma
     DFE Pharma
     Evonik
     Kirsch Pharma
     Merck KGaA
     Pfanstiehl
     Roquette
     Spectrum Chemical Manufacturing
     SPI Pharma

    For additional details, please visit
    https://www.rootsanalysis.com/reports/biopharmaceutical-excipient-manufacturing-market.html
    or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Gene Editing beyond CRISPR Market: Industry Trends and Global Forecasts, 2022-2035
    2. Cell and Gene Therapy Bioassay Services Market: Industry Trends and Global Forecasts, 2022-2035
    3. Thermostable Vaccines and Thermostable Biologics Market: Industry Trends and Global Forecasts, 2021-2035
    4. Protein Design and Engineering Market: Industry Trends and Global Forecasts, 2021-2035
    5. Next Generation Sequencing (NGS) Kits Market: Industry Trends and Global Forecast, 2021-2035

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com


    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The biopharmaceutical excipient manufacturing market is projected to grow at an annualized rate of 5.8% The demand for biopharmaceutical excipients has grown considerably in the past few years; they play a critical role in biologics development by enhancing the solubility and bioavailability, controlling pH and tonicity of the active pharmaceutical ingredients (APIs) Roots Analysis has announced the addition of “Biopharmaceutical Excipient Market” report to its list of offerings Owing to the highly complex and capital-intensive manufacturing processes of biopharmaceutical excipients, many contemporary biologic developers prefer to rely on CMOs for the supply of GMP grade excipients. In order to cater to the growing demand for biopharmaceutical excipients across both clinical and commercial scales, CMOs with expertise in this field are anticipated to expand their capabilities and existing capacities in the coming years. To order this 200+ page report, which features 75+ figures and 110+ tables, please visit https://www.rootsanalysis.com/reports/biopharmaceutical-excipient-manufacturing-market.html Key Market Insights Over 40 companies, across the world, claim to offer biopharmaceutical excipients Majority of the firms (34%) engaged in this domain are mid-sized players, followed by large firms (32%) and very large companies (19%). Close to 30% of the stakeholders were established post 2000. Further, 37% players are based in North America; within this region, the US emerged as a most prominent hub. Partnership activity within this domain has grown at a CAGR of 70%, between 2016 and 2021 Over 40 agreements have been inked in the last 5 years in this domain; 32% of which were distribution agreements. Other popular types of partnership models adopted by players engaged in this domain include acquisitions (23%) and supply agreements (13%). ~ 40% rise in expansion initiatives in this field, during the period 2016-2021 More than 45% of such initiatives were focused on capacity expansion of manufacturing facilities, followed by those undertaken for expanding existing facilities (43%). It is worth mentioning that most of expansion initiatives (78%) were carried out in Europe and North America. Approximately 95% of the total installed capacity is dedicated to commercial scale manufacturing The remaining 5% of the installed capacity is focused on preclinical / clinical scale manufacturing of biopharmaceutical excipients. In addition, over 50% of the total current global, installed biopharmaceutical excipient manufacturing capacity is installed in Europe. North America and Europe are anticipated to capture over 70% of the market share, by 2035 In addition, the market in Asia Pacific is likely to grow at a relatively faster pace (6.4%) in the long term. Further, in 2035, biopharmaceutical excipient manufacturing market for antibodies is expected to capture the majority share (~52%) of the total market. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/biopharmaceutical-excipient-manufacturing-market.html Key Questions Answered  Who are the key players engaged in biopharmaceutical excipient manufacturing?  Which global regions are considered as key hubs for biopharmaceutical excipient manufacturing?  What type of partnership models are commonly adopted by stakeholders in this industry?  What kind of expansion initiatives have been undertaken by biopharmaceutical excipient manufacturers?  What is current, global biopharmaceutical excipient manufacturing capacity of contract manufacturers?  How is the current and future market opportunity likely to be distributed across key market segments? The financial opportunity within the protein design and engineering services market has been analyzed across the following segments:  Type of Biologic  Antibodies  Vaccines  Cell and Gene Therapies  Other Biologics  Type of Excipient  Carbohydrates  Polymers  Solubilizers / Surfactants  Polyols  Proteins / Amino Acids  Others  Company Size  Small  Mid-Sized  Large / Very Large  Scale of Operation  Preclinical  Clinical  Commercial  Key Geographical Regions  North America  Europe  Asia-Pacific  Latin America  MENA  Rest of the World The report also features inputs from eminent industry stakeholders, according to whom, growing demand for biopharmaceutical excipients will drive the growth of manufacturers engaged in the biopharmaceutical excipient manufacturing domain, in the coming future. The research includes profiles of key players (listed below); each profile features a brief overview of the company, financial information (if available), details related to its biopharmaceutical excipients portfolio, manufacturing facilities, recent developments, and an informed future outlook.  ABITEC  Avantor  BASF  Corden Pharma  DFE Pharma  Evonik  Kirsch Pharma  Merck KGaA  Pfanstiehl  Roquette  Spectrum Chemical Manufacturing  SPI Pharma For additional details, please visit https://www.rootsanalysis.com/reports/biopharmaceutical-excipient-manufacturing-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Gene Editing beyond CRISPR Market: Industry Trends and Global Forecasts, 2022-2035 2. Cell and Gene Therapy Bioassay Services Market: Industry Trends and Global Forecasts, 2022-2035 3. Thermostable Vaccines and Thermostable Biologics Market: Industry Trends and Global Forecasts, 2021-2035 4. Protein Design and Engineering Market: Industry Trends and Global Forecasts, 2021-2035 5. Next Generation Sequencing (NGS) Kits Market: Industry Trends and Global Forecast, 2021-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Biopharmaceutical Excipient Manufacturing Market | Industry Analysis | Market Size | 2030
    Biopharmaceutical Excipient Manufacturing Market report features an extensive study of the current market landscape and future opportunity for the players involved in the development of clinical trials software...
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • Brooke's Chem-Dry Kansas City's trained cleaners use a safe and effective hot carbonated cleaning solution to give the best Carpet Cleaning in Kcmo Kansas City.

    Visit Here: https://carpetcleaningkansascitymissouri.com/carpet-cleaners-kansas-city/
    Brooke's Chem-Dry Kansas City's trained cleaners use a safe and effective hot carbonated cleaning solution to give the best Carpet Cleaning in Kcmo Kansas City. Visit Here: https://carpetcleaningkansascitymissouri.com/carpet-cleaners-kansas-city/
    0 Comments 0 Shares
  • Brooke's Chem-Dry Kansas City's trained cleaners use a safe and effective hot carbonated cleaning solution to give the best Carpet Cleaning in Kcmo Kansas City.

    Visit Here: https://carpetcleaningkansascitymissouri.com/carpet-cleaners-kansas-city/
    Brooke's Chem-Dry Kansas City's trained cleaners use a safe and effective hot carbonated cleaning solution to give the best Carpet Cleaning in Kcmo Kansas City. Visit Here: https://carpetcleaningkansascitymissouri.com/carpet-cleaners-kansas-city/
    Carpet Cleaner Kansas City
    Here you will get the best Carpet Cleaner service in Kansas City, Mo, Missouri, Kcmo, Parkville, Platte City Mo, Liberty and nearby areas with great Premier Carpet Cleaner options.
    CARPETCLEANINGKANSASCITYMISSOURI.COM
    0 Comments 0 Shares
  • Best Monkey Repellent Device in India

    Prompt Pest Control Equipments is the reputed manufacturer and supplier of monkey repeller in India. Our monkey repellent machine attacks monkeys' auditory and nervous systems and causes them pain and discomfort. This device has proven 100% effective for homes, schools, hospitals, etc. Visit us today to buy a top-quality monkey repeller.

    Source: https://promptpestcontrol.com/product/animal-repellents/monkey-repellent/

    #ultrasonicmonkeyrepeller #ultrasonicmonkeyrepellent #monkeycontrolequipment #monkeyrepellerIndia #monkeyrepellentIndia
    Best Monkey Repellent Device in India Prompt Pest Control Equipments is the reputed manufacturer and supplier of monkey repeller in India. Our monkey repellent machine attacks monkeys' auditory and nervous systems and causes them pain and discomfort. This device has proven 100% effective for homes, schools, hospitals, etc. Visit us today to buy a top-quality monkey repeller. Source: https://promptpestcontrol.com/product/animal-repellents/monkey-repellent/ #ultrasonicmonkeyrepeller #ultrasonicmonkeyrepellent #monkeycontrolequipment #monkeyrepellerIndia #monkeyrepellentIndia
    1
    0 Comments 0 Shares
  • Bc Movers Vancouver

    We at “Let’s Get Moving” are an award-winning moving company helping people have a seamless moving experience with their quality moving services.

    Being one of the moving companies in Toronto, we put in our best efforts to make customers moving journeys plain and simple. Moreover, when it comes to our full-service moving, we offer all-inclusive hourly rates for our full-service moving.

    #BcMoversVancouver

    Read More...
    Bc Movers Vancouver We at “Let’s Get Moving” are an award-winning moving company helping people have a seamless moving experience with their quality moving services. Being one of the moving companies in Toronto, we put in our best efforts to make customers moving journeys plain and simple. Moreover, when it comes to our full-service moving, we offer all-inclusive hourly rates for our full-service moving. #BcMoversVancouver Read More...
    Moving & Storage Company in Vancouver!
    Have an upcoming move in Vancouver? Contact our award-winning moving and storage company in Vancouver. Contact our Vancouver movers today!
    LETSGETMOVINGCANADA.COM
    0 Comments 0 Shares
  • The pharmaceutical contract manufacturing market is projected to grow at an annualized rate of ~7%, till 2030, claims Roots Analysis

    Driven by the COVID-19 pandemic and increasing demand for small molecules, the pharmaceutical contract manufacturing market is anticipated to witness significant growth over the next decade.

    Roots Analysis has announced the addition of “Pharmaceutical Contract Manufacturing Market (3rd Edition), 2021-2030” report to its list of offerings.

    The report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing industry. Amongst other elements, the report features:
     A detailed overview of the overall market landscape, featuring an elaborate list of over 450 active CMOs engaged in this domain, along with information on several relevant parameters, such as year of establishment, company size, geographical location of CMOs, type of business segment (active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs)), type of API(s) manufactured (complex, generic and sterile), type of FDF(s) offered (oral solids, liquids / semi-solids, injectables, inhalation and others), type of service(s) offered, type of primary packaging form (blister, tubes, vial / cartridge, ampoule, sachets / pouches / bags, inhalers / nasal sprays, glass / plastic / dropper bottles, pre-filled syringes / autoinjectors), scale of operation (preclinical, clinical and commercial) and specific location of manufacturing facilities (country-wise).
     A detailed analysis of various mergers and acquisitions that have taken place in this domain, highlighting the trend in number of companies acquired and geographical distribution of the activity, during the period 2017-2021. Further, it highlights the relationship between deal multiples (based on revenues), number of employees and experience of the acquired firm.
     A detailed analysis of the recent expansions (since 2017) undertaken by various service providers in order to augment their respective pharmaceutical contract manufacturing service portfolios, based on a several relevant parameters, such as year of expansion, purpose of expansion (capability expansion, capacity expansion, facility expansion, new facility), type of business segment (API(s), FDF(s)), capital invested, scale of operation (clinical, commercial), type of service(s) offered (formulation, manufacturing, packaging), geographical location of facility, and most active players (in terms of number of instances).
     An estimate of the global, installed capacity for the manufacturing of small-molecule drugs, based on information provided by various industry stakeholders in the public domain. It also features distribution of the available capacity on the basis of scale of operation (clinical and commercial), company size (small, mid-sized and large firms) and key geographical regions (North America, Europe and Asia Pacific).
     Informed estimates of the annual clinical and commercial demand for small molecule drugs, across key geographical regions.
     A detailed analysis of pharmaceutical contract manufacturing service providers’ capabilities in different regions, based on several relevant parameters, such as type of business segment, type of service(s) offered and type of packaging form.
     A detailed analysis of various pharmaceutical contract manufacturing service providers featuring schematic representations, including [A] a heat map analysis, highlighting the distribution of integrated contract service providers (companies offering manufacturing services for both small and large molecules), on the basis of location of their headquarters, year of establishment and number of employees, [B] a geographical landscape analysis, highlighting CMOs that have a wide geographical reach, on the basis of their presence (manufacturing facilities) across various regions, and [C] a grid representation, highlighting the global and regional trend of API and FDF outsourcing services, based on the location of headquarters of the company, number of employees, type of business segment, type of service(s) offered and scale of operation.
     A detailed discussion on various guidelines laid down by major regulatory bodies, across different countries, featuring an elaborative assessment of over 450 CMOs engaged in this domain, along with information on their operational approvals, certifications received, and relative popularity of the key regulatory body. Additionally, the chapter features an insightful multi-dimensional bubble analysis, presenting a comparison of the current regulatory scenario in key geographies.
     Elaborate profiles of key players engaged in offering pharmaceutical contract manufacturing services. Each profile features a brief overview of the company, along with information on its financial performance (if available), service(s) portfolio, manufacturing facilities and capabilities, recent developments and an informed future outlook.
     A case study highlighting a comparison of the key characteristics of large and small molecule drugs, along with information on the steps involved in their respective manufacturing processes.
     A qualitative analysis highlighting the various factors that need to be taken into consideration by pharmaceutical drug developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
     A detailed analysis capturing the key parameters and trends that are likely to influence the future of the pharmaceutical contract manufacturing market, under an elaborate SWOT framework. Further, it presents a schematic Harvey ball analysis highlighting the relative impact of each SWOT parameter on the overall pharmaceutical industry.

    To request a sample copy / brochure of this report, please visit
    https://www.rootsanalysis.com/reports/191/request-sample.html

     A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below):
     Type of Business Segment
     API
     FDF

     Type of API Manufactured
     Generics
     Originator

     Type of FDF Offered
     Oral Solids
     Parenteral
     Others

     Scale of Operation
     Clinical
     Commercial

     Type of Packaging Form Offered
     Bottles
     Blisters
     Injectables
     Others

     Type of End-User
     Small
     Mid-sized
     Large

     Region
     North America
     Europe
     Asia-Pacific
     Latin America
     Middle East and North Africa

    Key companies covered in the report
     AMRI Global
     Altasciences
     Cambrex
     Catalent
     DPT Laboratories
     Thermo Fisher Scientific
     Aenova Group
     Almac Group
     Corden Pharma
     Fresenius Kabi
     Glatt
     Hovione
     Recipharm
     Siegfried
     CMIC Group
     Nectar Lifesciences
     Syngene
     WuXi AppTec

    For more information, please click on the following link:
    https://www.rootsanalysis.com/reports/view_document/pharmaceutical-contract-manufacturing-market/191.html or email sales@rootsanalysis.com

    Other Recent Offerings
    1. Vaccine Contract Manufacturing Market (3rd Edition): Industry Trends and Global Forecasts, 2021-2030
    2. Pharmaceutical Contract Research Services Market: Industry Trends and Global Forecasts, 2021-2030
    3. Biopharmaceutical Contract Manufacturing Market (4th Edition): Industry Trends and Global Forecasts, 2021-2030

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/

    The pharmaceutical contract manufacturing market is projected to grow at an annualized rate of ~7%, till 2030, claims Roots Analysis Driven by the COVID-19 pandemic and increasing demand for small molecules, the pharmaceutical contract manufacturing market is anticipated to witness significant growth over the next decade. Roots Analysis has announced the addition of “Pharmaceutical Contract Manufacturing Market (3rd Edition), 2021-2030” report to its list of offerings. The report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing industry. Amongst other elements, the report features:  A detailed overview of the overall market landscape, featuring an elaborate list of over 450 active CMOs engaged in this domain, along with information on several relevant parameters, such as year of establishment, company size, geographical location of CMOs, type of business segment (active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs)), type of API(s) manufactured (complex, generic and sterile), type of FDF(s) offered (oral solids, liquids / semi-solids, injectables, inhalation and others), type of service(s) offered, type of primary packaging form (blister, tubes, vial / cartridge, ampoule, sachets / pouches / bags, inhalers / nasal sprays, glass / plastic / dropper bottles, pre-filled syringes / autoinjectors), scale of operation (preclinical, clinical and commercial) and specific location of manufacturing facilities (country-wise).  A detailed analysis of various mergers and acquisitions that have taken place in this domain, highlighting the trend in number of companies acquired and geographical distribution of the activity, during the period 2017-2021. Further, it highlights the relationship between deal multiples (based on revenues), number of employees and experience of the acquired firm.  A detailed analysis of the recent expansions (since 2017) undertaken by various service providers in order to augment their respective pharmaceutical contract manufacturing service portfolios, based on a several relevant parameters, such as year of expansion, purpose of expansion (capability expansion, capacity expansion, facility expansion, new facility), type of business segment (API(s), FDF(s)), capital invested, scale of operation (clinical, commercial), type of service(s) offered (formulation, manufacturing, packaging), geographical location of facility, and most active players (in terms of number of instances).  An estimate of the global, installed capacity for the manufacturing of small-molecule drugs, based on information provided by various industry stakeholders in the public domain. It also features distribution of the available capacity on the basis of scale of operation (clinical and commercial), company size (small, mid-sized and large firms) and key geographical regions (North America, Europe and Asia Pacific).  Informed estimates of the annual clinical and commercial demand for small molecule drugs, across key geographical regions.  A detailed analysis of pharmaceutical contract manufacturing service providers’ capabilities in different regions, based on several relevant parameters, such as type of business segment, type of service(s) offered and type of packaging form.  A detailed analysis of various pharmaceutical contract manufacturing service providers featuring schematic representations, including [A] a heat map analysis, highlighting the distribution of integrated contract service providers (companies offering manufacturing services for both small and large molecules), on the basis of location of their headquarters, year of establishment and number of employees, [B] a geographical landscape analysis, highlighting CMOs that have a wide geographical reach, on the basis of their presence (manufacturing facilities) across various regions, and [C] a grid representation, highlighting the global and regional trend of API and FDF outsourcing services, based on the location of headquarters of the company, number of employees, type of business segment, type of service(s) offered and scale of operation.  A detailed discussion on various guidelines laid down by major regulatory bodies, across different countries, featuring an elaborative assessment of over 450 CMOs engaged in this domain, along with information on their operational approvals, certifications received, and relative popularity of the key regulatory body. Additionally, the chapter features an insightful multi-dimensional bubble analysis, presenting a comparison of the current regulatory scenario in key geographies.  Elaborate profiles of key players engaged in offering pharmaceutical contract manufacturing services. Each profile features a brief overview of the company, along with information on its financial performance (if available), service(s) portfolio, manufacturing facilities and capabilities, recent developments and an informed future outlook.  A case study highlighting a comparison of the key characteristics of large and small molecule drugs, along with information on the steps involved in their respective manufacturing processes.  A qualitative analysis highlighting the various factors that need to be taken into consideration by pharmaceutical drug developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.  A detailed analysis capturing the key parameters and trends that are likely to influence the future of the pharmaceutical contract manufacturing market, under an elaborate SWOT framework. Further, it presents a schematic Harvey ball analysis highlighting the relative impact of each SWOT parameter on the overall pharmaceutical industry. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/191/request-sample.html  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below):  Type of Business Segment  API  FDF  Type of API Manufactured  Generics  Originator  Type of FDF Offered  Oral Solids  Parenteral  Others  Scale of Operation  Clinical  Commercial  Type of Packaging Form Offered  Bottles  Blisters  Injectables  Others  Type of End-User  Small  Mid-sized  Large  Region  North America  Europe  Asia-Pacific  Latin America  Middle East and North Africa Key companies covered in the report  AMRI Global  Altasciences  Cambrex  Catalent  DPT Laboratories  Thermo Fisher Scientific  Aenova Group  Almac Group  Corden Pharma  Fresenius Kabi  Glatt  Hovione  Recipharm  Siegfried  CMIC Group  Nectar Lifesciences  Syngene  WuXi AppTec For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/pharmaceutical-contract-manufacturing-market/191.html or email sales@rootsanalysis.com Other Recent Offerings 1. Vaccine Contract Manufacturing Market (3rd Edition): Industry Trends and Global Forecasts, 2021-2030 2. Pharmaceutical Contract Research Services Market: Industry Trends and Global Forecasts, 2021-2030 3. Biopharmaceutical Contract Manufacturing Market (4th Edition): Industry Trends and Global Forecasts, 2021-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Request Sample - Pharmaceutical Contract Manufacturing Market | Market Size | Industry Analysis | 2030
    Pharmaceutical Contract Manufacturing Market report features an extensive study of the current market landscape and future potential of the...
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The “Biopharmaceutical Contract Manufacturing Market (3rd edition), 2019 – 2030” report

    Over the years, the rising popularity of biologics has led to a paradigm shift in healthcare. In the last decade alone, the annual number of approvals of biopharmaceuticals, by the US FDA, have steadily risen.

    To order this 750+ page report, please visit this - https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html

    Key Inclusions
     A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters, such as scale of operation (preclinical, clinical and commercial), type of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression systems used (mammalian, microbial and others), year of establishment, employee size, geographical location of the CMO, number of manufacturing facilities, as well as the location of these facilities, GMP compliance, affiliations to regulatory agencies, type of bioreactors used (single-use bioreactors and stainless steel bioreactors), mode of operation of bioreactors (batch, fed-batch and perfusion) and bioprocessing capacity.
     Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biologics. Each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), as well as a comprehensive future outlook.
     A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.
     A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.
     A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
     A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.
     An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics; the analysis is based on various parameters, such as the year in which the agreement was signed, type of agreement, focus area and type of biologics.
     A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity. The analysis also depicts the relationship between important deal multiples based on the revenue, number of employees and experience of the acquired company.
     An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions. In addition, it provides information on the technology advancements related to biomanufacturing.
     A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders (small-sized, mid-sized, large and very large CMOs / CDMOs) in the market, using data from both secondary and primary research. The study examines the distribution of global biopharmaceutical manufacturing capacity by scale of operation (preclinical / clinical, commercial), size of company (small-sized, mid-sized, large and very large), and geography (North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia and Middle East (China, India, Japan, South Korea and rest of the Asia and Middle East), and rest of the world (including Australia).
     An informed estimate of the annual demand for biologics, taking into account the top 20 biologics, based on a various relevant parameter, such as target patient population, dosing frequency and dose strength of the abovementioned products.
     A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.
     A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.

    The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
     Commonly Outsourced Business Operations
     Active Pharmaceutical Ingredients (API)
     Finished Dosage Formulations (FDF)
     Types of Expression System
     Mammalian
     Microbial
     Others
     Company Size
     Small
     Mid-Sized
     Large and Very Large
     Scale of Operation
     Preclinical
     Clinical
     Commercial
     Key Geographical Region
     North America
     Europe
     Asia-Pacific

    To request sample pages, please visit this - https://www.rootsanalysis.com/reports/250/request-sample.html

    Key Questions Answered
     Who are the key manufacturers (industry / non-industry) of cell-based therapies, across the world?
     What is the global demand for biologics-based therapies?
     What are the major recent developments (such as partnerships and expansions) in this industry?
     What kind of partnership models are commonly adopted by stakeholders in this domain?
     What is the current, installed contract manufacturing capacity for biologics?
     How is the current and future market opportunity likely to be distributed across key market segments?


    For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html


    You may also be interested in the following titles:
    1. Cell Therapy Manufacturing Market (3rd Edition), 2019-2030
    2. Antibody Contract Manufacturing Market, 2020-2030
    3. China Biopharmaceutical Contract Manufacturing Market, 2020-2030
    4. Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030




    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The “Biopharmaceutical Contract Manufacturing Market (3rd edition), 2019 – 2030” report Over the years, the rising popularity of biologics has led to a paradigm shift in healthcare. In the last decade alone, the annual number of approvals of biopharmaceuticals, by the US FDA, have steadily risen. To order this 750+ page report, please visit this - https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html Key Inclusions  A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters, such as scale of operation (preclinical, clinical and commercial), type of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression systems used (mammalian, microbial and others), year of establishment, employee size, geographical location of the CMO, number of manufacturing facilities, as well as the location of these facilities, GMP compliance, affiliations to regulatory agencies, type of bioreactors used (single-use bioreactors and stainless steel bioreactors), mode of operation of bioreactors (batch, fed-batch and perfusion) and bioprocessing capacity.  Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biologics. Each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), as well as a comprehensive future outlook.  A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.  A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.  A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.  A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.  An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics; the analysis is based on various parameters, such as the year in which the agreement was signed, type of agreement, focus area and type of biologics.  A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity. The analysis also depicts the relationship between important deal multiples based on the revenue, number of employees and experience of the acquired company.  An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions. In addition, it provides information on the technology advancements related to biomanufacturing.  A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders (small-sized, mid-sized, large and very large CMOs / CDMOs) in the market, using data from both secondary and primary research. The study examines the distribution of global biopharmaceutical manufacturing capacity by scale of operation (preclinical / clinical, commercial), size of company (small-sized, mid-sized, large and very large), and geography (North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia and Middle East (China, India, Japan, South Korea and rest of the Asia and Middle East), and rest of the world (including Australia).  An informed estimate of the annual demand for biologics, taking into account the top 20 biologics, based on a various relevant parameter, such as target patient population, dosing frequency and dose strength of the abovementioned products.  A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.  A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers. The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:  Commonly Outsourced Business Operations  Active Pharmaceutical Ingredients (API)  Finished Dosage Formulations (FDF)  Types of Expression System  Mammalian  Microbial  Others  Company Size  Small  Mid-Sized  Large and Very Large  Scale of Operation  Preclinical  Clinical  Commercial  Key Geographical Region  North America  Europe  Asia-Pacific To request sample pages, please visit this - https://www.rootsanalysis.com/reports/250/request-sample.html Key Questions Answered  Who are the key manufacturers (industry / non-industry) of cell-based therapies, across the world?  What is the global demand for biologics-based therapies?  What are the major recent developments (such as partnerships and expansions) in this industry?  What kind of partnership models are commonly adopted by stakeholders in this domain?  What is the current, installed contract manufacturing capacity for biologics?  How is the current and future market opportunity likely to be distributed across key market segments? For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html You may also be interested in the following titles: 1. Cell Therapy Manufacturing Market (3rd Edition), 2019-2030 2. Antibody Contract Manufacturing Market, 2020-2030 3. China Biopharmaceutical Contract Manufacturing Market, 2020-2030 4. Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    0 Comments 0 Shares
  • China Biopharmaceutical Contract Manufacturing Market - Gaining Traction in the Pharmaceutical Industry

    The “China Biopharmaceutical Contract Manufacturing Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of biopharmaceuticals in China. The study also features a detailed analysis of key drivers and trends related to this evolving domain.

    The current biopharmaceuticals market is characterized by high quality standards and a rapidly growing demand for novel and effective treatment options. It is, therefore, a technically challenging industry in which outsourcing has grown into a promising and prominent segment, especially for manufacturing and fill / finish operations. Outsourcing biopharmaceutical manufacturing operations to Asia is increasing at a rapid pace. In this, China has emerged as an attractive destination for outsourcing.

    To request a sample report: https://www.rootsanalysis.com/reports/313/request-sample.html

    Driven by rapid technological development, and an increasingly favorable policy landscape, the Chinese biopharmaceutical industry is projected to witness significant growth in the coming years. Considering the complications associated with the production and handling of biologic drugs, biopharmaceutical developers are always on the lookout for reliable contract service providers. As a result, CMOs / CDMOs in China have invested significant capital and other resources in order to develop the required scientific acumen, technical expertise and production capacity for biopharmaceuticals, over the past decade. As a result, several indigenous players currently claim to offer services and solutions at par with world-class biopharmaceutical CMOs and CDMOs. Further, several service provider companies based in developed regions, have also established wholly / partially owned facilities in this region. This strategic shift in location of manufacturing operations enables the aforementioned players to leverage the various region-specific advantages, related to biopharmaceutical manufacturing, which China has to offer.

    To order customize report: https://www.rootsanalysis.com/reports/china-biopharmaceutical-contract-manufacturing/request-customization.html

    Further, the recent approval of the market authorization holder (MAH) system on a national level, which was being run as a pilot program in several provinces since 2016, is a big achievement. This has led to an increase in outsourcing contracts to players based in China, which is further expected to decrease the idle capacity of CMOs, thereby reducing overall cost and increasing productivity; it is worth mentioning that, owing to rise in expansion initiatives carried out by biopharmaceutical CMOs in this region, over 50% of the biomanufacturing capacity is estimated to be idle / not utilized. In addition, as multiple biologics are likely to lose their patent exclusivity in the near future, the demand for biosimilars, especially monoclonal antibody (mAb) therapeutics, is expected to rise. Since these products cannot be marketed at exorbitant prices, firms often outsource their manufacturing operations to emerging regions, such as China, to enable savings; this is further likely to boost the growth of the Chinese biopharmaceutical CMOs market. Some the main advantages of outsourcing manufacturing operations to China-based CMOs / CDMOs are briefly described below:
     Availability of Skilled Labor: The country has a large pool of educated and capable individuals who are qualified to work in biopharmaceutical manufacturing plants. The recent increase in stringency of immigration policies, coupled to a scarcity of jobs in the developed regions, have cause many Chinese nationals to return to China. Such individuals, who have been trained in the West, are highly likely to be hired by Chinese firms. Further, a number of biopharmaceutical companies, such as Boehringer Ingelheim, GE Healthcare, Merck and Thermo Fisher Scientific, have either already established, or are planning to establish, manufacturing operations in China. This is anticipated to create several job opportunities for scientists and pharma workers in the region.
     Cost Advantages: Labor in developing regions, such as China, is much less expensive when compared to the US and Europe. This has garnered the interest of many multinational biopharmaceutical companies, especially those based in developed regions, causing them to offshore a lot of their production operations.
     Access to a Large Indigenous Marketplace: Product manufactured in China are granted easier access to the local market. On the other hand, regulations in China are actually prohibitive when it comes to foreign developers attempting to sell their offerings in the Chinese market. Considering the fact that the country is home to one of the largest populations, the region does offer a lucrative marketplace.
    Evolving Regulatory Framework and Government Support: The Chinese government is very supportive of local economic development, offering subsidies and incentives to indigenous initiatives. The introduction of the MAH guidelines, which provided special allowances for approval of drugs manufactured by contract organizations offered a significant boost to the contract services industry in the region.


    For more information, please click on the following link:
    https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html

    You may also be interested in the following reports:
    1. Peptide Therapeutics
    2. Biopharmaceutical Excipient Manufacturing Market
    3. Single-use Sensors for Bioprocessing Market


    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    China Biopharmaceutical Contract Manufacturing Market - Gaining Traction in the Pharmaceutical Industry The “China Biopharmaceutical Contract Manufacturing Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of biopharmaceuticals in China. The study also features a detailed analysis of key drivers and trends related to this evolving domain. The current biopharmaceuticals market is characterized by high quality standards and a rapidly growing demand for novel and effective treatment options. It is, therefore, a technically challenging industry in which outsourcing has grown into a promising and prominent segment, especially for manufacturing and fill / finish operations. Outsourcing biopharmaceutical manufacturing operations to Asia is increasing at a rapid pace. In this, China has emerged as an attractive destination for outsourcing. To request a sample report: https://www.rootsanalysis.com/reports/313/request-sample.html Driven by rapid technological development, and an increasingly favorable policy landscape, the Chinese biopharmaceutical industry is projected to witness significant growth in the coming years. Considering the complications associated with the production and handling of biologic drugs, biopharmaceutical developers are always on the lookout for reliable contract service providers. As a result, CMOs / CDMOs in China have invested significant capital and other resources in order to develop the required scientific acumen, technical expertise and production capacity for biopharmaceuticals, over the past decade. As a result, several indigenous players currently claim to offer services and solutions at par with world-class biopharmaceutical CMOs and CDMOs. Further, several service provider companies based in developed regions, have also established wholly / partially owned facilities in this region. This strategic shift in location of manufacturing operations enables the aforementioned players to leverage the various region-specific advantages, related to biopharmaceutical manufacturing, which China has to offer. To order customize report: https://www.rootsanalysis.com/reports/china-biopharmaceutical-contract-manufacturing/request-customization.html Further, the recent approval of the market authorization holder (MAH) system on a national level, which was being run as a pilot program in several provinces since 2016, is a big achievement. This has led to an increase in outsourcing contracts to players based in China, which is further expected to decrease the idle capacity of CMOs, thereby reducing overall cost and increasing productivity; it is worth mentioning that, owing to rise in expansion initiatives carried out by biopharmaceutical CMOs in this region, over 50% of the biomanufacturing capacity is estimated to be idle / not utilized. In addition, as multiple biologics are likely to lose their patent exclusivity in the near future, the demand for biosimilars, especially monoclonal antibody (mAb) therapeutics, is expected to rise. Since these products cannot be marketed at exorbitant prices, firms often outsource their manufacturing operations to emerging regions, such as China, to enable savings; this is further likely to boost the growth of the Chinese biopharmaceutical CMOs market. Some the main advantages of outsourcing manufacturing operations to China-based CMOs / CDMOs are briefly described below:  Availability of Skilled Labor: The country has a large pool of educated and capable individuals who are qualified to work in biopharmaceutical manufacturing plants. The recent increase in stringency of immigration policies, coupled to a scarcity of jobs in the developed regions, have cause many Chinese nationals to return to China. Such individuals, who have been trained in the West, are highly likely to be hired by Chinese firms. Further, a number of biopharmaceutical companies, such as Boehringer Ingelheim, GE Healthcare, Merck and Thermo Fisher Scientific, have either already established, or are planning to establish, manufacturing operations in China. This is anticipated to create several job opportunities for scientists and pharma workers in the region.  Cost Advantages: Labor in developing regions, such as China, is much less expensive when compared to the US and Europe. This has garnered the interest of many multinational biopharmaceutical companies, especially those based in developed regions, causing them to offshore a lot of their production operations.  Access to a Large Indigenous Marketplace: Product manufactured in China are granted easier access to the local market. On the other hand, regulations in China are actually prohibitive when it comes to foreign developers attempting to sell their offerings in the Chinese market. Considering the fact that the country is home to one of the largest populations, the region does offer a lucrative marketplace. Evolving Regulatory Framework and Government Support: The Chinese government is very supportive of local economic development, offering subsidies and incentives to indigenous initiatives. The introduction of the MAH guidelines, which provided special allowances for approval of drugs manufactured by contract organizations offered a significant boost to the contract services industry in the region. For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html You may also be interested in the following reports: 1. Peptide Therapeutics 2. Biopharmaceutical Excipient Manufacturing Market 3. Single-use Sensors for Bioprocessing Market About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Request Sample - China Biopharmaceutical Contract Manufacturing | Industry Analysis | Market Size | 2030
    Market research report on China biopharmaceutical contract manufacturing industry, with focus on current market landscape and 2030 market size
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares

No results to show

No results to show

No results to show

Sponsored